15 AI News Updates That Broke The Internet

14. Lantern Pharma Inc. (NASDAQ:LTRN)

Number of Hedge Fund Holders: 3

Lantern Pharma Inc. (NASDAQ:LTRN) is an artificial intelligence (AI) company that develops precision oncology therapies. On December 3, the company announced that the FDA has granted Fast Track Designation for its investigational drug LP-184 to treat Triple Negative Breast Cancer (TNBC). This is the second Fast Track Designation received for LP-184 in 2024 after it received its first for Glioblastoma in October. Currently, LP-184 is in a Phase1A clinical trial for assessing the safety and tolerability of the investigational drug candidate in a broad range of solid tumors, including TNBC. Moreover, LP-184 has been developed with Lantern’s AI platform, RADR®, helping validate mechanisms that could be exploited in the clinical setting and that can target tough-to-treat cancers and improve outcomes for specific patient groups.

“Receiving a second FDA Fast Track Designation for LP-184 reinforces the significant potential of this drug candidate to address critical unmet needs in aggressive cancers, especially those like TNBC where patients have limited therapeutics options. Recent data presented at the Immuno-Oncology Summit demonstrated LP-184’s ability to sensitize TNBC tumors that are non-responsive to checkpoint inhibitors, potentially expanding treatment options for patients with limited therapeutic choices”.

-Panna Sharma, President and CEO of Lantern Pharma.